Skip to content

Daily Weight Study

Daily Weight Study - Daily Weight Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00025586
Enrollment
40
Registered
2021-06-23
Start date
2021-05-21
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N17.92 N17.93

Interventions

Group 1: Intervention group: Weigh daily for a period of seven days. Group 2: Control

Sponsors

Charité Universitätsmedizin BerlinKlinik für Nephrologie und internistische Intensivmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: *AKI KDIGO 2 or 3 *No marked haemodynamic instability (noradrenaline up to a maximum of 0.3microg/min, no adrenaline, assessment of the attending physician)

Exclusion criteria

Exclusion criteria: *Failure to obtain patient consent or revocation of same. *Ecmo therapy *Noradrenaline level lower 0,05 microgram/minute

Design outcomes

Primary

MeasureTime frame
Daily weighing will give patients a cumulatively lower fluid balance over 7 days after inclusion in the study.

Secondary

MeasureTime frame
Daily weighing leads to faster recovery from AKI. Daily weighing leads to fewer dialysis treatments in the first 4 weeks. Daily weighing leads to shorter ITS stay.

Countries

Germany

Contacts

Public ContactPhilipp Enghard

Charité Universitätsmedizin BerlinKlinik für Nephrologie und internistische Intensivmedizin

philipp.enghard@charite.de030 450 614 016

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026